ConcertAI

Executive Summary

ConcertAI is a private company based in Cambridge, Massachusetts, founded in 2017. It leverages generative AI and real-world data (RWD) to transform oncology clinical research and improve patient outcomes. By integrating AI-driven analytics with RWD, ConcertAI accelerates trial design, patient recruitment, and evidence generation for biopharma partners. The company operates at the intersection of AI/ML, oncology, and digital health, offering solutions that reduce development timelines and costs while increasing trial success rates. With a focus on precision medicine, ConcertAI's platform enables faster identification of eligible patients, predictive modeling for treatment response, and real-time monitoring of trial progress. Despite being private with limited public financial data, the company has likely gained traction through partnerships with top pharmaceutical companies and academic medical centers, given its niche in high-value oncology RWD. The growing demand for AI-driven clinical trial solutions, coupled with the expansion of RWD sources, positions ConcertAI for continued growth in the coming years.

Upcoming Catalysts (preview)

• H2 2026Announcement of a major partnership with a top-10 pharmaceutical company for AI-powered trial design70% success
• Q1 2027Launch of a new generative AI module for real-world evidence generation in rare oncology indications60% success
• H1 2027Series C funding round led by a prominent healthcare VC, with disclosed valuation increase55% success